Showing results (1-10 of 92) with videos related to
Sort By:
Pageof 10
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1987
Allogeneic H-2 antigen expression is insufficient for tumor rejectionG A Cole, G A Cole, V K Clements, et al.Journal of Immunogenetics|August 1, 1989
Transfection of major histocompatibility complex class I and class II genes causes tumour rejectionS Ostrand-Rosenberg, V K Clements, A Thakur, et al.International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1991
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesS Ostrand-Rosenberg, C Roby, V K Clements, et al.Cellular Immunology|June 1, 1990
Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous hostS Ostrand-Rosenberg, G A Cole, M I Nishimura, et al.Cellular Immunology|May 1, 1991
Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4-CD8+ T lymphocytes that are not lytic for the tumorG A Cole, S Ostrand-RosenbergSeminars in Cancer Biology|October 1, 1991
Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejectionS Ostrand-Rosenberg, E P Garcia, C A Roby, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 4, 1998
Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivoT D Armstrong, V K Clements, S Ostrand-RosenbergJournal of Immunology (Baltimore, Md. : 1950)|December 1, 1993
Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejectionE Lamousé-Smith, V K Clements, S Ostrand-RosenbergJournal of Immunology (Baltimore, Md. : 1950)|April 29, 1998
MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytesT D Armstrong, V K Clements, S Ostrand-RosenbergJournal of Immunology (Baltimore, Md. : 1950)|November 22, 2000
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinomaS Ostrand-Rosenberg, M J Grusby, V K ClementsPageof 10